{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To assess whether eltrombopag decreases the incidence of grade 3/4 thrombocytopenic events by day 1 of Cycle 3 of chemotherapy","groups":[{"description":"Administration of eltrombopag to support platelets during chemotherapy\n\nEltrombopag: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy","id":"OG000","title":"Migration Arm"}],"populationDescription":"Terminated with 1 patient enrolled; no data due to patient privacy.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Incidence of Grade 3/4 Thrombocytopenic Events","type":"SECONDARY"}